Aurobindo Pharma Share Price Rises After Q4 Revenue Growth

Aurobindo Pharma's share price rose over 2% on Monday following the announcement of its Q4 FY25 results. The pharmaceutical giant reported a consolidated revenue increase of 10.6% year-on-year, reaching Rs 8,382 crore, surpassing Bloomberg's estimate of Rs 8,197 crore.

Despite a slight dip in net profit, which fell by 0.6% to Rs 903.5 crore due to higher interest costs, depreciation expenses, and increased tax liabilities, the company's overall performance was buoyed by revenue growth across its business segments. The Ebitda rose by 7% to Rs 1,792 crore, although it fell short of the estimated Rs 1,827 crore. The Ebitda margin narrowed slightly to 21.4% from 22%, against an estimated 22.3%.

Aurobindo Pharma's US formulations segment showed growth, with revenue increasing by 13.5% to Rs 4,072 crore. Similarly, the Europe formulations segment saw a rise of 17.2% year-on-year, reaching Rs 2,147 crore.

The company's net profit was impacted by a higher share of loss from associates and joint ventures, which amounted to Rs 32 crore compared to Rs 12 crore last year.

The scrip rose as much as 2.20% to Rs 1,206 apiece. It pared gains to trade 2.01% higher at Rs 1,204 apiece, as of 09:47 a.m. This compares to a 0.81% advance in the NSE Nifty 50.

It has risen 0.69% in the last 12 months. Total traded volume so far in the day stood at 2.1 times its 30-day average. The relative strength index was at 51.

Out of 29 analysts tracking the company, 23 maintain a 'buy' rating, two recommend a 'hold' and four suggest 'sell', according to Bloomberg data. The average 12-month consensus price target implies an upside of 25.2%.